Drugs and the Liver

Rosenoer, Victor M.; Tornay, Anthony S.

doi:10.1016/s0025-7125(16)31705-9

Cited by 5 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Between 4% and 20% of women using Stimate Ò have reported headaches [15,37]. The patient should also be asked about a history of liver disease, not only for the obvious reason that an associated coagulopathy could cause menorrhagia, but for the practical reason that the use of OC for control of menorrhagia may be contraindicated in patients with chronic hepatitis or elevation of their liver function tests [38]. A history of anxiety disorder may also be relevant as a recent study from Scharrer et al [39] reported a 28% prevalence of a generalized anxiety disorder in 181 women with vWD (141 were type 1, the remaining type 2 and 3).…”

Section: Past Medical Historymentioning

confidence: 99%

Menorrhagia from a haematologist's point of view. Part I: initial evaluation

Kouides

2002

Haemophilia

View full text Add to dashboard Cite

The evaluation of menorrhagia should no longer be solely the task of the gynaecologist. In women with ovulatory bleeding (regular cycles), the prevalence of von Willebrand disease (vWD) in about 15% of these, as well as disorders of platelet function and fibrinolysis causing menorrhagia, warrants an active role by the haematologist. Initial intake should include documentation of menorrhagia by the pictorial chart assessment of menstrual flow. Baseline characteristics of menstrual flow should also be documented, including the frequency of changing the sanitary pad on the heaviest day, use of more than one sanitary pad at a time, number of days lost from school/work and the impact of menses on various quality-of-life parameters. Menorrhagia since menarche, a past history of surgical- and/or dental-related bleeding and a past history of postpartum haemorrhage are items of the bleeding symptom audit that appear in part to predict vWD in women with menorrhagia. Epistaxis and easy bruising do not appear to be clearly discriminatory symptoms. Initial testing should include the complete blood cell count, prothrombin time, activated partial thromboplastin time, iron profile, serum creatinine, thyroid stimulating hormone level, factor VIII level, vWF antigen, ristocetin cofactor and platelet aggregation studies. Additional haemostatic studies may also include a factor XI level and euglobulin clot lysis time. This extensive medical evaluation should assure both the patient and the gynaecologist that the possibility of an underlying haemostatic disorder has been thoroughly investigated, to avoid the patient undergoing further costly procedures and surgical interventions if an underlying haemostatic disorder remains unrecognized.

show abstract

Section: Past Medical Historymentioning

confidence: 99%

Menorrhagia from a haematologist's point of view. Part I: initial evaluation

Kouides

2002

Haemophilia

View full text Add to dashboard Cite

show abstract

“…The folic acid antagonist methotrexate is used widely in human beings to treat various types of malignant tumours (Cline & Haskell, 1980;Custer et al, 1977;Rosenoer & Tornay, 1979), and as a means of controlling psoriasis (Custer et al, 1977). Methotrexate is also being used with increasing frequency to treat animals with malignant tumours, including lymphoma (MacEwan et al, 1977) and osteosarcoma (Henness et al, 1977).…”

Section: Introductionmentioning

confidence: 99%

“…Acute toxicity associated with methotrexate therapy is manifested by bone marrow suppression and ulceration of the gastrointestinal tract (Cline & Haskell, 1980;Rosenoer & Tornay, 1979;Chadner, 1979). Toxicity associated with long term administration of methotrexate includes liver damage, lung damage, and osteoporosis (Cline & Haskell, 1980;Chadner, 1979;Custer et al, 1977).…”

Section: Introductionmentioning

confidence: 99%

“…There are many clinical reports of liver damage in human beings treated with methotrexate for prolonged periods. Lesions described include fatty metamorphosis (Millward Sadler & Ryan, 1974;Zimmerman, 1979), fibrosis (Zimmerman, 1979; Rosenoer & Tornay, 1979;Ruymann et al, 1977), hepatocyte necrosis (Millward Sadler & Ryan, 1974;Zimmerman, 1979), cirrhosis (Zimmerman, 1979;Rosenoer & Tornay, 1979;Ruymann et al, 1977), and in one case hepatoma (Ruymann et al, 1977).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatotoxicity associated with methotrexate therapy in a dog

Pond

Morrow

1982

J of Small Animal Practice

View full text Add to dashboard Cite

A nine‐year‐old male Newfoundland‐cross was treated with doxorubicin, cyclophosphamide, and methotrexate as adjuvant chemotherapy following the resection of a maxillary osteosarcoma. The dog remained in good health until week 13 of therapy, when he became anorexic, and developed icterus and ascites. Laboratory tests at this time suggested sub‐acute hepatic failure and renal failure. Necropsy revealed severe generalized hepatic necrosis with resultant ascites and intestinal haemorrhage. Since there was no evidence on necropsy of an infectious aetiology, and since there was no history of toxin ingestion, methotrexate which is a known hepatotoxin in man, was considered the probable cause of the hepatic necrosis. This side‐effect of methotrexate has not previously been reported in the dog, and animals undergoing therapy with the drug should be monitored closely for hepatotoxicity.

show abstract

“…Ο πιθανός υπεύθυνος μηχανισμός φαίνεται ότι είναι η ακετυλίωση της ισονιαζίδης από κάποιο ενζυμικό σύστημα που είναι γενετικά καθορισμένο και υπεύθυνο για την ταχεία ή βραδεία ακετυλίωση της ισονιαζίδης και για τη διάσπαση της σχηματιζόμενης ακετυλοϊσονιαζίδης σε ελεύθερη ακετυλυδραζίνη που οξειδώνεται από το κυτόχρωμα Ρ 450 σε κάποιο χη μικά δραστικό ακυλιούντα παράγοντα που προκαλεί τις ιστικές αλλοιώ σεις. Θα πρέπει επίσης να σημειώσουμε ότι άλλοι συγγραφείς αναφέ ρουν αυξημένη συχνότητα ηπατοτοξικότητας της ισονιαζίδης, όταν αυτή χορηγείται σε αρρώστους αλκοολικούς ή που λαμβάνουν ταυτόχρονα και ριφαμπικίνη (44,45), ενώ άλλοι αναφέρουν ότι σε τέτοιους αρρώστους δεν παρατηρήθηκε στατιστικά σημαντική διαφορά ηπατοτοξικότητας (45,46,47,48). Η ηπατοπάθεια από την ισονιαζίδη εμφανίζει σχέση με την ηλικία του αρρώστου και η συχνότητα της αυξάνεται πάνω από την ηλικία των 35 ετών και ιδιαίτερα στο γηριατρικό πληθυσμό (49).…”

Section: ινωδολυτικό σύστημαunclassified

Οι Μεταβολες Του Ινωδογονου Και Της Αντιθρομβινης Ιιι Στη Διαρκεια Της Ληψης Ισονιαζιδης Και Ριφαμπικινης

Φαρμακησ¹

View full text Add to dashboard Cite

Drugs and the Liver

Cited by 5 publications

References 11 publications

Menorrhagia from a haematologist's point of view. Part I: initial evaluation

Menorrhagia from a haematologist's point of view. Part I: initial evaluation

Hepatotoxicity associated with methotrexate therapy in a dog

Οι Μεταβολες Του Ινωδογονου Και Της Αντιθρομβινης Ιιι Στη Διαρκεια Της Ληψης Ισονιαζιδης Και Ριφαμπικινης

Contact Info

Product

Resources

About